Reported 1 day ago
Iovance Biotherapeutics, known for its innovative melanoma treatment Amtagvi, may have a potential upside of 261% according to Wall Street, despite facing challenges such as high costs and complex administration processes. Though Amtagvi is generating growing sales, the company risks running out of cash within a year and may encounter regulatory hurdles. Investors should weigh the high risks against the potential rewards before considering an investment.
Source: YAHOO